A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
暂无分享,去创建一个
T. Waldmann | H. Kohrt | H. Wakelee | D. McNeel | Jeffrey S. Miller | M. Cheever | C. Morishima | M. Disis | John A Thompson | K. Conlon | P. Sondel | J. C. Kaiser | S. Creekmore | H. Streicher | M. Patel
[1] S. Ferrone,et al. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy , 2017, Immunological investigations.
[2] F. Pan,et al. Foxp3, Regulatory T Cell, and Autoimmune Diseases , 2016, Inflammation.
[3] A. Vella,et al. Regulatory T Cells and Cancer: A Two-Sided Story , 2016, Immunological investigations.
[4] R. Busuttil,et al. Immunological battlefield in gastric cancer and role of immunotherapies. , 2016, World journal of gastroenterology.
[5] James R. Eshleman,et al. Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.
[6] J. Vicario,et al. A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. , 2015, Cytotherapy.
[7] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[8] T. Waldmann,et al. Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20 , 2015 .
[9] David L Porter,et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.
[10] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Hao Liu,et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Jie Chen,et al. Chemotherapy-Induced miRNA-29c/Catenin-δ Signaling Suppresses Metastasis in Gastric Cancer. , 2015, Cancer research.
[13] T. Waldmann. The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy , 2015, Cancer Immunology Research.
[14] S. Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[15] Sadik H. Kassim,et al. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.
[16] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[17] M. Wadhwa,et al. Detection of anti-cytokine antibodies and their clinical relevance , 2014, Expert review of clinical immunology.
[18] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[19] Bin Zhang,et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. , 2014, Blood.
[20] A. Ghazalpour,et al. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[21] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[22] S. D. De Rosa,et al. Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay. , 2012, Journal of visualized experiments : JoVE.
[23] K. Flaherty,et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[24] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[25] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[26] M. Sneller,et al. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. , 2011, Blood.
[27] T. Waldmann,et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. , 2011, Blood.
[28] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[29] M. Atkins,et al. White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy , 2011, Clinical Cancer Research.
[30] S. Antonia,et al. Indoleamine 2,3-Dioxygenase: Is It an Immune Suppressor? , 2010, Cancer journal.
[31] S. Steinberg,et al. Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy , 2010, Clinical Cancer Research.
[32] T. Waldmann,et al. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer , 2009, Proceedings of the National Academy of Sciences.
[33] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[34] Alexia Iasonos,et al. A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies , 2008, Clinical trials.
[35] J. Schlom,et al. Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2 , 2007, Clinical Cancer Research.
[36] T. Waldmann. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.
[37] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[38] T. Waldmann,et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. , 2005, Blood.
[39] T. Waldmann,et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[40] T. Waldmann,et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Steinberg,et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.
[43] T. Waldmann,et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Caligiuri,et al. Interleukin 15: biology and relevance to human disease. , 2001, Blood.
[45] T. Waldmann,et al. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.